Will Novo Nordisk’s CagriSema reach 25% weight loss in REDEFINE 11?

Question

This market will resolve YES if Novo Nordisk’s final primary REDEFINE 11 result reports mean body-weight reduction of at least 25.0% from baseline at week 80 for the CagriSema 2.4 mg/2.4 mg treatment group under the efficacy estimand, the analysis assuming adherence to assigned treatment. Exactly 25.0% qualifies. A lower reported mean resolves NO; the percentage of participants losing some weight is a different measure.

Use the whole specified treatment arm, not a responder subgroup, an extensi

Problyx · Accepted Answer

No — the community forecast puts this at 67%.

Problyx · Answer

Yes — the community forecast puts this at 33%.